CONTEXTO: A transfusão sanguínea destaca-se entre os fatores de risco implicados na transmissão dos vírus das hepatites B (VHB) e C (VHC); entretanto não há relatos da transmissão endoscópica destes vírus em pacientes com esquistossomose na forma hepatoesplênica. OBJETIVO: Estimar a prevalência dos marcadores sorológicos do VHB e VHC em pacientes com esquistossomose hepatoesplênica e avaliar os possíveis fatores de risco associados a essas infecções. MÉTODOS: Estudo do tipo transversal, com 230 pacientes com esquistossomose hepatoesplênica atendidos em um Hospital Universitário de Recife, PE, Brasil, no período de fevereiro a agosto de 2008. Os pacientes responderam a um questionário padronizado sobre os fatores de risco. Nas amostras de soro foram pesquisados o anti-HBc total, o anti-HBs, o HBsAg e o anti-VHC por ensaio imunoenzimático. As análises estatísticas utilizadas foram a univariada e a regressão logística múltipla. RESULTADOS: Encontrou-se prevalencia de 30% para anti-HBc total e/ou HBsAg e 7,4% para o anti-VHC. Houve maior frequencia de pacientes positivos do sexo feminino e idade .50 anos para os marcadores analisados. Verificou-se associação significativa entre a presenca do anti-HCV e a categoria de seis ou mais transfusões. Nao foi constatada associação do antecedente e numero de endoscopias digestivas com os marcadores sorologicos analisados. CONCLUSÕES: Constatou-se maior prevalência de marcadores sorológicos do VHB e menor prevalência para o anti-VHC. Evidenciou-se o sexo feminino e paciente de idade avançada como as categorias mais atingidas e maior probabilidade da infecção pelo VHC em pacientes politransfundidos.

CONTEXT: Blood transfusion is one of the major risk factors for the transmission of the hepatitis B (HBV) and C (HCV) viruses. However, there are no reports describing the endoscopic transmission of these viruses in patients with the hepatosplenic form of schistosomiasis. OBJECTIVE: To estimate the prevalence of serological markers of HBV and HCV in patients with the hepatosplenic form of schistosomiasis and evaluate the possible risk factors associated with these infections. METHODS: A cross-sectional study was conducted on 230 patients with hepatosplenic form of schistosomiasis who attended a university hospital in Recife, Northeastern Brazil, from February to August 2008. The patients answered a standardized questionnaire about risk factors. Serum samples were analyzed for anti-HBc total, anti-HBs, HBsAg, and anti-HCV using enzyme-linked immunosorbent assays. Univariate analysis and multiple logistic regression were performed. RESULTS: The prevalence was 30% for anti-HBc total and/or HBsAg and 7.4% for anti-HCV. There was a higher frequency of the serological markers in females and in patients aged .50 years. A significant association was detected between the presence of anti-HCV and the receipt of six or more blood transfusions. There was no association of history and number of digestive endoscopies with the serological markers analyzed. CONCLUSIONS: We observed a higher prevalence of serological markers for HBV and a lower prevalence of anti-HCV. Our results indicate that females and patients of an advanced age are the most affected categories and that patients that received multiple transfusions are at a higher probability of HCV infection.

Praziquantel chemotherapy has been the focus of the Schistosomiasis Control Program in Brazil for the past two decades. Nevertheless, information on the impact of selective chemotherapy against Schistosoma mansoni infection under the conditions confronted by the health teams in endemic municipalities remains scarce. This paper compares the spatial pattern of infection before and after treatment with either a 40 mg/kg or 60 mg/kg dose of praziquantel by determining the intensity of spatial cluster among patients at 180 and 360 days after treatment. The spatial-temporal distribution of egg-positive patients was analysed in a Geographic Information System using the kernel smoothing technique. While all patients became egg-negative after 21 days, 17.9% and 30.9% reverted to an egg-positive condition after 180 and 360 days, respectively. Both the prevalence and intensity of infection after treatment were significantly lower in the 60 mg/kg than in the 40 mg/kg treatment group. The higher intensity of the kernel in the 40 mg/kg group compared to the 60 mg/kg group, at both 180 and 360 days, reflects the higher number of reverted cases in the lower dose group. Auxiliary, preventive measures to control transmission should be integrated with chemotherapy to achieve a more enduring impact.

Patients with acute schistosomiasis were studied before and after oxamniquine treatment. They had been exposed to cercariae 5 to 9 weeks before, and presented compatible clinical manifestations, eosinophilia, and high levels of total IgE. Interferon-gamma (IFN-gamma) and interleukin-4 were measured by ELISA in whole blood samples under soluble egg antigen or soluble adult worm preparation stimulation. After treatment, the reduction of leukocytosis and eosinophilia were not significant, but total IgE levels decreased significantly, in contrast to IFN-gamma levels that were significantly increased. The oxamniquine treatment of acute schistosomiasis patients is followed by an improvement of a Th1 response in vitro. If this response has a protective aspect is unknown, and some investigations need to be realized.

Evaluation of hepatic fibrosis is usually performed by histopathological examination of biopsies. However, this is an invasive and potentially dangerous procedure. Several studies have proposed serum biological markers of hepatic fibrosis. This communication evaluates the use of serum cytokines as markers of hepatic fibrosis in hepatitis C, schistosomiasis, and co-infection.

Portal hypertension is a frequent complication of chronic liver disease, detected not only in schistosomiasis, but also in cirrhosis of any etiology. Vascular alterations in the colonic mucosa are a potential source for acute or chronic bleeding and have been observed in patients with portal hypertension. The purpose of this prospective study was to describe and propose a classification for the vascular alterations of portal hypertension in the colonic mucosa among patients with hepatosplenic schistosomiasis mansoni. One or more alterations of portal colopathy were observed in all patients and they were classified according to their intensity, obeying the classification proposed by the authors. Portal colopathy is an important finding in hepatosplenic schistosomiasis and might be the cause of lower gastrointestinal bleeding in patients with severe portal hypertension.

Specific IgG and IgM responses to soluble egg antigen (SEA) and keyhole limpet haemocyanin (KLH) were measured by ELISA in patients with acute and chronic schistosomiasis. The tests based upon IgM and IgG antibodies responses to KLH presented the best diagnostic discrimination, and can be used in conjunction with clinical and epidemiological data to the differential diagnosis of acute schistosomiasis.

The production and regulation of interleukin (IL) IL-13, IL-4 and interferon-gamma was evaluated in different clinical forms of human schistosomiasis. The mechanisms of immune regulation are apparently different in the various clinical stages of the disease, some of them being antigen specific.

Two contiguous villages in Tracunhaém county (State of Pernambuco), endemic for schistosomiasis, were studied: Itapinassu (138 inhabitants) and São Joaquim (91 inhabitants). Agriculture predominates in the former region while ceramics is the main activity in the latter. Although no statistical difference was found regarding prevalence, severe infection (>400 epg) predominated in Itapinassu, probably related to the kind of occupation. No association was found between parasite burden and severity of disease, in spite of the high infection rates for Schistosoma mansoni in both communities (approx. 60%). Typical epidemiological features of schistosomiasis such as age-related prevalences and intensities of infection (high in children, low in adults) were also mutual characteristics. Nutritional status determined through anthropometric evaluation was carried out by measuring specific anthropometric indicators. A deficit of energy intake, as well as vitamin A and riboflavin deficiencies were detected. The prevalence of moderate or severe undernutrition in patients under 18 years old was 21.9% in Itapinassu and 24.1% in São Joaquim. In this group an association was found between prevalence of schistosomiasis and chronic undernutrition. Similarly, for patients over 18 year old the prevalence of undernutrition was higher than 20%. However, in this case no association between nutritional status and either prevalence of schistosomiasis or parasite burden could be detected. The two communities had not been treated for eight years.

Quarenta e dois pacientes esquistossomóticos hepatosplênícos, tratados com praziquantel, foram acompanhados por cinco anos. Metade dos pacientes recebeu uma dose simples de 30mg/kg; a outra metade, recebeu duas doses de 25mg/kg dadas com intervalos de 4 horas. A taxa de cura, de acordo com os exames de fezes pelos métodos de Hoffman cols e de Kato-Katz, durante 12 meses foi de 83,3%. Nos casos com cura incompleta, os ovos contados nas fezes foram muito reduzidos. A função hepática, estimada pelo nível, no soro, de aspartato aminotransferase,, alamina aminotransferase, gama glutamiltransferase e fosfatase alcalina bem como, de albumina e gama globulina mostrou acentuada melhora após um ano. Hepatomegalia foi reduzida em 81,0% dos pacientes e esplenomegalia em 78,8%. A regressão do baço foi completa em 15,1% do total e em 18,5% daqueles com forma hepatosplênica compensada. Como resultado destas observações, os autores recomendam tratamento precoce com medicação antiesquistossomótica com oxamniquine ou praziquantel para interromper a progressão da doença e reduzir hepatomegalia e esplenomegalia.

Forty-two with hepatosplenic patients treated with praziquantel and followed up for 5 years. One half of the patients received a single 30 mg/kg dose and the other half, two doses of 25 mg/kg given 4 hrs apart. According to Hoffman and Kato-Katz stool exams, an 83.3% cure rate, was observed after twelve months. Stool egg counts in cases of incomplete cure were greatly reduced. Liver function, as assessed by serum levels of aspartate aminotransferase, alanine aminotransferase, gamma glutamyltransferase and alkaline phosphatase activities as well as albumin and gamma globulin showed marked improvement after one year. Hepatomegaly was reduced in 81.0% of patients and splenomegaly in 78.8%. Spleen regression was complete in 15.1% of the total, and in 18.5% of those with compensated hepatosplenic disease. As a result of these observations, the authors recomend early treatment with anti-schistosomal medication, either oxamniquine or praziquantel, to halt progression of disease and reduce splenomegaly.

Noventa e quatro pacientes, 22 do sexo masculino e 72 do feminino, com idades variando de 11 a 71 anos, média de 25, apresentando a forma hepatesplênica da esquistossomose mansônica, foram tratados com uma nova droga antiesquistossomótica — praziquantel — objetivando-se investigar sua eficácia e tolerância. Duas doses orais — 1 x 30 e 2 x 25 mg/kg — foram comparadas. Efeitos colaterais foram verificados durante os primeiros dois dias seguintes à administração da droga, mas usualmente de média intensidade e curta duração. Os mais freqüentes e, por vezes, mais severos foram: dor ou desconforto abdominal, diarréia, tontura, cefaléia e náusea. Febre esteve presente em 19,2% dos casos e urticaria e prurido em dois pacientes. A investigação laboratorial mostrou, em alguns casos, ligeiras alterações enzimáticas (AST, ALT, γ-GT) 24 horas após a medicação. Nenhuma modificação da urinálise, da glicose sangüínea e dos dados hematológicos foi detectada, exceto o aumento comumente observado dos eosinófilos nos 7." e 30.° dias, relacionado à morte dos parasitas dentro do organismo. Da mesma forma, nenhuma anormalidade foi verificada no estudo eletroencefalográfico. Na eletrocardiografia, observou-se, em duas pacientes, uma ligeira e transitória alteração na repolarização ventricular. No que diz respeito à cura parasitológica, constatou-se, em 62 pacientes que concluíram seis meses de controle, um porcentual global de cura de 80,6%, sendo de 76,7% com a dose de 30 mg/lkg e de 84,4% com a de 2 x 25 mg/kg. Os pacientes não curados tiveram, por outro lado, uma acentuada redução no número de ovos do S. mansoni eliminados nas fezes. Além disso, cinco pacientes não curados, foram retratados seis ou mais meses depois, com a mesma dose inicial, obtendo-se 100°/o de negatividade nos exames de fezes. Os Autores acreditam que com a administração de doses um pouco mais altas como, por exemplo, 60 mg/kg, se possa obter um maior porcentual de cura, sem prejuízo da boa tolerância. A melhora clínica e laboratorial a longo prazo, isto é, seis ou mais meses após a medicação, foi marcante em todos os parâmetros estudados.

Ninety-four patients, 22 males and 72 females, from 11 to 71 years old, with an average of 25 years, presenting the hepatosplenic form of Schistosomiasis mansoni were treated with a new anthelmintic drug — praziquantel — to investigate its efficacy and tolerance. In addition to the hepatosplenic form of the disease, 14 patients had the cardio-pulmonary hypertensive or cyanotic form and 16 had already been submitted to splenectomy. Two oral doses — 1 x 30 and 2 x 25 mg/kg body weight — were compared. Side-effects were noticed during the first two days following the drug administration but usually of mild intensity and short duration. The most frequent and, at times, more severe were abdominal pain or discomfort, diarrhea, headache, dizziness and nausea. Fever was present in 19.2% of the cases and urticaria and pruritus in two patients. The laboratorial investigation of liver function showed, in some cases, slight enzymatic alterations (AST, ALT, y GT) 24 hours after medication, but without any major significance. No urinary, blood glucose or hematological changes have been detected, except, for the commonly seen increase of eosinophyls on the 7th and 30th day, related to the death of parasites inside the organism. Likewise, no abnormality was noticed in the electroencephalografic study. In the electrocardiogram it was observed in two patients a slight and transitory modification on the ventricular repolarization. With regard to the parasitological cure, it was observed in 62 patients Who have finished the 6 months control period, a total cure rate of 80.6%. With 30 mg/kg single dose this cure rate was 76.7% and with 25 mg/kg b.i.d. 84.4%. The non-cured patients, on the other hand, have shown a marked reduction in the number of S. mansoni eggs eliminated in the feces. Furthermore, five of these patients Were retreated six or more months afterwards with the same initial dose, achieving 100% negative stool examinations. The Authors believe that administering a higher dose, like 60 mg/kg, it would be possible to accomplish, in addition to good tolerance, a greater percentage of parasitological cure. The long-term clinical and laboratory improvement, observed 6 and 12 months after treatment, is worthy of note.

São apresentados os resultados preliminares do tratamento da esguistossomose mansônica com oxamniquine, sob forma de xarope, em 40 crianças, com idade variando de 5 a 14 anos. 18 pertenciam ao sexo masculino e 22 ao feminino. A dose utilizada foi de 20 mg/k em uma única aplicação - 25 pacientes (Grupo A) ou em 2 tomadas com intervalo de 12 hs - 15 pacientes (Grupo B). A tolerância foi em geral boa, sobretudo no Grupo B de pacientes, onde 73,3% não apresentou qualquer sintoma colateral, em comparação com 44% do Grupo A. 0s sintomas mais freqüentes foram tontura (22,5%) e sonolência (20%). 5 pacientes do Grupo A apresentaram distúrbio de conduta sob forma de excitação psíquica ou agressividade passageiras. A cura parasitológica (comprovação entre o 4º e o 6º mês pós-tratamento) foi observada em 70% dos pacientes tratados (90% no Grupo A e 50% no Grupo B). O baixo índice, nesse último Grupo, possivelmente deveu-se ao longo intervalo entre as 2 tomadas (12hs). Houve grande redução do número de ovos eliminados nos pacientes não curados.

The authors present the results of the treatment of 40 children (5 to 14 years) with oxamniquine syrup; 25 of them were given a single dose of 20 mg/kg b.w. and 15 received the same total dose divided at 12 hours intervals. Tolerance was good; 22,5% had dizziness and 20%, drowsiness; 5 patients of the first group presented psychological disturbances. 70% of the patients presented parasitological cure 4 to 6 months after treatment; (90% em Group A and 5% in Group B) a marked egg count reduction was observed.